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Abstract
Rationale: Most studies determining the prevalence of airway
obstruction are limited to short time periods.
Objectives: Because temporal trends of obstruction in populations
are largely unknown, we determined the prevalence of airway
obstruction over 20 years in yearly general population samples in
Switzerland between 1993 and 2012.
Methods: We analyzed data of 85,789 participants aged 35 years
and older who provided spirometric measurements as part of the
LuftiBus lung function campaign. We linked data from the 2003–
2012 period to the Swiss National Cohort to adjust for annual
population differences. Spirometry was performed without
bronchodilation, according to American Thoracic Society
guidelines. We used Global Lung Initiative (GLI) and Hankinson
reference equations to identify obstruction.
Results: Obstruction prevalence increased between 1993 and 2012
from 6.1% (95% confidence interval [CI], 5.5 to 6.7) to 15.6% (95%
CI, 13.8 to 17.3) based on GLI estimates and from 5.3% (95%
CI, 4.7 to 5.9) to 15.4% (95% CI, 13.6 to 17.1) based on Hankinson
estimates. When adjusted for participant demographics, air
pollutant and occupational exposures, altitude, and season, the
prevalence ratios of obstruction were 1.54 (95% CI, 1.22 to 1.93)
and 1.65 (95% CI, 1.33 to 2.04) for GLI- and Hankinson-
defined airway obstruction, respectively, for 2012 compared with
2003.
Conclusions: Though prebronchodilator measurements likely
overestimate the prevalence of airway obstruction in absolute
terms compared with post-bronchodilator measurements, we
found an increase in airway obstruction prevalence. Even with
adjustment for several well-known risk factors for obstruction to
make the populations across the years more comparable, we still
saw a statistically significant increase in prevalence over this time
period.
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Chronic lung diseases characterized by
airway obstruction (AO), such as asthma or
chronic obstructive pulmonary disease
(COPD), contribute substantially to
morbidity and mortality worldwide.
Although asthma is the most prevalent
obstructive lung disease, COPD is the third
leading cause of death (1). COPD and AO
are insidious in that the latency period for
the development of clinically significant
disease takes several decades, and there are
many known and potentially unavoidable
risk factors, such as outdoor air pollution,
smoking, and occupational exposures.
Authors of a recent systematic review (2)
found large global variation in COPD
prevalence, ranging from 9.7% in Southeast
Asia to 13.7% in Europe and 15.2% in the
North and South American regions in 2010.
Such prevalence estimates of AO or COPD
are based primarily on cross-sectional
studies with one reference date.
Repeated cross-sectional and
longitudinal prevalence study designs exist.
However, these designs are rare, hindered by
time-consuming data collection and large–
sample size demands. Nevertheless, studies
with repeated measurements provide rich
information because they can be used to
reveal patterns of change in temporal trends.
These studies show a wide range of
prevalence trends across countries (3–13).
Some of the differences in prevalence trends
may be due to methodological variation,
study populations, and lung function
equipment or performance, making a
comparison of prevalence data difficult. The
few temporal trend studies on AO carry
limitations: They are often restricted to two
reference dates, are based on physician-
diagnosed COPD instead of spirometric
measures, or use the fixed-ratio criteria
(3, 5, 6, 8–11). Although some temporal
trend studies analyzed factors affecting
prevalence, such as occupational exposures
or outdoor air pollution, they similarly
included either just two reference dates or a
subset of these exposures (3, 4). Given these
considerations, there is a lack of temporal
trend studies on AO that include multiple
reference dates and adjust for risk factors
that confound temporal trend estimates.
Our aim was to assess the temporal
trend of AO prevalence from 1993 to 2012 in
Switzerland, a country that offers great
diversity in terms of its population,
geography, and exposures associated with
AO. We performed a series of sensitivity
analyses to test the robustness of the trend
estimates and included important
confounders in our analyses.
Methods
Study Design and Population
The full description of our methodology
can be found in the online supplement.
We used a cohort of 85,789 adults in a
series of 18 prevalence studies from 1993
to 2012 for the primary analysis (Figure 1),
comprising data from the LuftiBus project
of the Zurich Lung Association, a not-
for-profit health organization (www.
lunge-zuerich.ch/de/projekte/luftibus),
and the Swiss National Cohort (SNC)
(www.swissnationalcohort.ch). The
LuftiBus drove around Switzerland between
1993 and 2012, offering spirometry and
other tests (e.g., exercise capacity tests) as
well as preventative/therapeutic services for
lung diseases to the general population. The
SNC is a nationwide, census-based cohort
combining individual data from the federal
population censuses taken in 2000 and 2012,
covering all residents of Switzerland.
For the secondary analysis, we linked
the 2003–2012 LuftiBus data with the SNC
to incorporate important risk factors for AO
and demographics for participants. The
years before 2003 could not be linked to the
SNC, owing to a lack of person-identifying
data for the linkage. We were left with a
cohort of 29,189 subjects for this analysis
(Figure 1). We conducted sensitivity
analyses by looking at the subgroup of 1,175
participants who self-reported having
asthma as well as 18,597 participants who
reside in the Canton of Zurich. The Ethics
Committee of the Canton of Zurich
approved this study (BASEC-Nr. 2017-
01804).
Because no date of birth in the LuftiBus
data was available for 1993–2002, these
years could not be linked with the SNC.
Hence, we conduct two separate analyses: 1)
The primary analysis provides yearly,
adjusted prevalence data of AO from 1993 to
2012; and 2) the secondary analysis provides
predicted marginal probabilities of AO
based on the 2003–2012 data with
adjustments for additional important
confounders (Figure 1).
Spirometry
Spirometry was performed during the
LuftiBus assessment using a computerized
pneumotachograph (SensorMedics Vmax
Legacy 20c spirometer with Vision 7-2b
software; Viasys). In 2005, the device was
replaced with the SensorMedics Vmax
Encore 20c, and in 2011, it was replaced with
the CareFusion MasterScreen Pneumo
(Vyaire Medical). We defined AO diagnosis
as a forced expiratory volume in 1 second
over forced vital capacity (FEV1/FVC) ratio
below the lower limit of normal using the
equation derived from the Global Lung
Initiative’s (GLI’s) reference values for
spirometry (14), by the Hankinson reference
equations (15), and the Global Initiative for
Chronic Obstructive Lung Disease (GOLD)
criteria of FEV1/FVC less than 0.7 (16). We
defined AO as meeting these criteria for
COPD diagnosis; however, because only
prebronchodilator data were used, we
refrain from calling the outcome “COPD.”
Statistical Analysis
All analyses were conducted using R version
3.6 software (17). The primary analysis was
a generalized linear model with GLI,
Hankinson, and GOLD AO as the outcome
using Poisson error distribution and robust
standard errors. We used these models to
plot the predicted marginal probabilities
annually, stratified by sex and smoking
status. To include more confounders in the
1993–2012 dataset, we linked postal codes
from the 2003 to 2012 dataset. Because of an
inability to link postal codes to the year
2002, that year was not included in the plots.
To guide visualization of the prevalence
trends, we applied locally weighted
regression (locally estimated scatterplot
smoothing [loess]) for nonparametric
smoothing (18).
To make the demographics across the
years more comparable, the regression
models were adjusted for age, sex, body
mass index, smoking status, residential
distance to major roads, urbanization,
residential altitude, and season of LuftiBus
measurement. Age, sex, body mass index,
and smoking status were included in the
analysis as important demographic
confounders for AO. We used residential
distance to major roads (.5,000 average
daily traffic) and urbanization as composite
markers for outdoor air pollution because
evidence suggests these are associated with
COPD (19–21). Residential altitude and
season were included to adjust for
differences in location and time of year.
For the secondary analysis, we
calculated the predicted marginal
probabilities of GLI-, Hankinson-, and
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GOLD-defined AO annually using Poisson
regression, with the year 2003 as a reference
using the 2003–2012 LuftiBus-SNC dataset.
These models were adjusted for the same
risk factors as above, with the inclusion of
education level; occupational exposure to
vapors, gases, dusts, or fumes (VGDF); and
participation in COPD Roadshow. Both
education level and VGDF are shown
to be correlated with AO (22–25). The
COPD Roadshow was included because
participants were more likely to have higher
rates of lung disease than the general
population.
We performed additional analyses to
check the robustness of the observed
temporal trend. We repeated the
adjusted analysis, isolating the Canton
of Zurich. This canton includes one-sixth
of the Swiss population and is the most
represented throughout 2003–2012, and the
demographic is representative of the overall
demographic of Switzerland (26, 27). We
also annually calculated the proportion of
Swiss National Cohort (SNC)
   N=7,288,010 (census 2000)
   N=8,039,060 (census 2012)
Excluded (n=12,016)
•  No acceptable link to census 2000
   records (6,173)
•  >1 linkage possibilities (5,843)
Excluded (n=44,053)






•  BMI <15 or >50 (126)
•  Lung League (524)
Excluded (n=13,081)
•  Age <35 years
Excluded (n=1,801)
•  BMI <15 or >50 (26)
•  FEV1 <0.3 liters or FEV1% <12% (15)
•  FEV1 > FVC (2)
•  No education data (1,234)









Linkage of LuftiBus cohort with







Converting from long to wide format (n=4,082)
• Merging of multiple observations from the
  same subject
Records excluded (n=16,252)
•  Missing data in sex, date of birth, or residential
   postcode, invalid postcodes, duplicates,
   multiple observations per subject and month
Figure 1. Study flowchart. BMI = body mass index; FEV1= forced expiratory volume in 1 second; FVC= forced vital capacity; SNC=Swiss National Cohort.
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Table 1. Demographics, by year
1993 1994 1995 1996 1997 1998 1999 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
n 5,875 5,215 5,529 4,830 5,560 3,277 5,291 4,512 4,498 2,844 2,052 4,033 3,536 2,795 2,959 2,541 3,405 3,645 1,155
Age, yr 55.8 (13.4) 53.6 (12.2) 54.0 (12.7) 53.9 (12.5) 54.3 (12.7) 55.0 (13.2) 55.1 (12.9) 56.0 (13.2) 57.8 (13.2) 58.6 (13.3) 56.8 (13.2) 58.6 (13.2) 58.1 (12.9) 58.3 (12.8) 56.9 (13.1) 57.9 (12.8) 58.3 (12.3) 59.6 (12.5) 58.9 (12.7)
Sex, M 2,393 (41%) 2,531 (49%) 2,770 (50%) 2,265 (47%) 2,615 (47%) 1,465 (45%) 2,369 (45%) 1,948 (43%) 1,830 (41%) 1,174 (41%) 1,055 (51%) 1,792 (44%) 1,641 (46%) 1,283 (46%) 1,444 (49%) 1,178 (46%) 1,599 (47%) 1,779 (49%) 578 (50%)
Males
BMI, kg/m2 25.3 (3.2) 25.3 (3.2) 25.3 (3.1) 25.4 (3.2) 24.5 (4.1) 25.4 (3.4) 25.6 (3.3) 25.7 (3.3) 25.7 (3.3) 25.9 (3.5) 25.6 (3.3) 25.8 (3.5) 25.9 (3.4) 25.9 (3.4) 26.1 (3.6) 25.9 (3.5) 25.9 (3.3) 26.3 (3.7) 26.3 (3.6)
Height, cm 174.0 (6.9) 174.6 (6.8) 174.7 (6.8) 174.9 (7.0) 174.8 (7.0) 175.1 (7.1) 174.5 (7.0) 174.4 (6.9) 174.6 (7.1) 174.1 (6.9) 175.9 (7.2) 175.2 (7.1) 175.5 (6.9) 175.8 (6.8) 176.1 (7.0) 175.6 (6.8) 176.0 (6.8) 175.8 (6.8) 176.0 (6.9)
Weight, kg 76.5 (10.8) 77.0 (10.7) 77.2 (10.8) 77.7 (10.7) 77.7 (10.9) 78.0 (11.2) 78.0 (11.2) 78.0 (11.2) 78.3 (11.1) 78.7 (11.6) 79.1 (11.3) 79.1 (11.9) 79.9 (11.6) 80.1 (11.7) 81.0 (12.1) 79.8 (11.7) 80.2 (11.5) 81.4 (12.8) 81.6 (13.0)
Females
BMI, kg/m2 24.1 (3.9) 24.3 (4.2) 24.4 (4.0) 24.1 (3.9) 24.5 (4.1) 24.2 (4.2) 24.6 (4.2) 24.6 (4.1) 24.6 (4.2) 25.2 (4.5) 25.0 (4.4) 24.5 (4.2) 24.6 (4.2) 24.3 (4.2) 24.7 (4.4) 24.4 (4.3) 24.4 (4.1) 24.7 (4.5) 24.9 (4.6)
Height, cm 162.3 (6.5) 162.5 (6.6) 162.4 (6.4) 162.9 (6.4) 162.6 (6.4) 162.5 (6.6) 162.9 (6.7) 162.9 (6.5) 163.0 (6.5) 161.9 (6.6) 162.8 (6.6) 162.5 (6.8) 163.4 (6.3) 163.9 (6.4) 163.4 (6.7) 163.4 (6.6) 164.0 (6.1) 163.7 (6.2) 163.9 (6.4)
Weight, kg 63.3 (10.5) 64.0 (11.5) 64.2 (10.8) 63.8 (10.5) 64.7 (11.1) 63.7 (10.9) 65.2 (11.2) 65.2 (11.1) 65.3 (11.4) 65.8 (11.6) 66.0 (11.8) 64.8 (11.6) 65.7 (11.6) 65.2 (11.4) 65.9 (12.0) 65.3 (12.0) 65.5 (11.4) 66.1 (12.1) 66.9 (13.3)
Higher education 657 (23%) 675 (33%) 1,148 (28%) 1,023 (29%) 901 (32%) 787 (27%) 768 (30%) 1,083 (32%) 1,047 (29%) 378 (33%)
Smoking status
Current 1,467 (25%) 1,083 (21%) 1,247 (23%) 1,000 (21%) 1,177 (21%) 566 (17%) 1,020 (19%) 813 (18%) 783 (18%) 445 (16%) 391 (19%) 744 (18%) 632 (18%) 441 (16%) 552 (19%) 384 (15%) 478 (14%) 615 (17%) 207 (18%)
Ex-smoker 1,082 (18%) 1,067 (20%) 1,225 (22%) 1,060 (22%) 1,163 (21%) 652 (20%) 1,066 (20%) 825 (18%) 937 (21%) 652 (24%) 561 (27%) 1,078 (27%) 942 (27%) 668 (24%) 750 (25%) 731 (29%) 890 (26%) 955 (26%) 272 (24%)
Never 2,782 (47%) 2,719 (52%) 2,684 (49%) 2,519 (52%) 2,935 (53%) 1,904 (58%) 3,005 (57%) 2,725 (60%) 2,568 (58%) 1,579 (57%) 1,052 (51%) 2,118 (53%) 1,832 (52%) 1,642 (59%) 1,604 (54%) 1,387 (55%) 1,958 (58%) 1,962 (54%) 630 (55%)
Passive 544 (9%) 346 (7%) 373 (7%) 251 (5%) 285 (5%) 155 (5%) 200 (4%) 149 (3%) 158 (4%) 87 (3%) 45 (2%) 89 (2%) 124 (4%) 44 (2%) 52 (2%) 37 (1%) 74 (2%) 110 (3%) 44 (4%)
Distance to major roads, m 621 (924) 515 (745) 473 (897) 473 (930) 595 (934) 640 (886) 744 (1,488) 661 (1,316) 525 (905) 533 (1,086)
Urbanization
Urban 513 (18%) 626 (31%) 1,253 (31%) 1,001 (28%) 572 (20%) 383 (13%) 506 (20%) 668 (20%) 620 (17%) 301 (26%)
Periurban 1,905 (67%) 1,227 (60%) 2,368 (59%) 1,888 (53%) 1,916 (69%) 1,987 (67%) 1,663 (65%) 2,270 (67%) 2,509 (69%) 722 (63%)
Rural 426 (15%) 199 (10%) 412 (10%) 647 (18%) 307 (11%) 589 (20%) 372 (15%) 467 (14%) 516 (14%) 132 (11%)
Season of assessment
Spring 1,897 (32%) 1,368 (26%) 1,224 (22%) 1,559 (32%) 1,672 (30%) 948 (29%) 1,345 (25%) 1,453 (32%) 1,397 (31%) 709 (25%) 1 (0%) 1,474 (37%) 1,081 (31%) 814 (29%) 890 (30%) 875 (34%) 646 (19%) 838 (23%) 744 (54%)
Summer 1,019 (17%) 1,396 (27%) 1,273 (23%) 1,279 (26%) 1,677 (30%) 1,159 (35%) 1,220 (23%) 842 (19%) 1,667 (37%) 662 (23%) 261 (13%) 1,142 (28%) 720 (20%) 657 (24%) 871 (29%) 504 (20%) 858 (25%) 810 (22%) 361 (31%)
Fall 1,372 (23%) 1,321 (25%) 1,585 (29%) 1,016 (21%) 1,644 (30%) 849 (26%) 1,468 (28%) 1,611 (36%) 820 (18%) 1,344 (47%) 1,657 (81%) 1,050 (26%) 1,477 (42%) 1,103 (39%) 1,056 (36%) 1,004 (40%) 1,745 (51%) 1,732 (48%) 0 (0%)
Winter 1,587 (27%) 1,130 (22%) 1,447 (26%) 976 (20%) 567 (10%) 321 (10%) 1,258 (24%) 606 (13%) 614 (14%) 129 (5%) 133 (6%) 367 (9%) 258 (7%) 221 (8%) 142 (5%) 158 (6%) 156 (5%) 265 (7%) 50 (4%)
Definition of abbreviation: BMI = body mass index.
Data are presented asmean (standard deviation) or number of subjects (percent). No information on education, distance tomajor roads, and urbanization was available for the years 1993–2002,

















































In Figure 3, we saw Hankinson-defined
AO increased for both sexes. Prevalence of
female current smokers in 1993 was 10.1%
and increased to 29.1% by 2012. Although
Hankinson reported higher rates of AO for
women in all smoking categories, for males,
the Hankinson rates tended to be lower than
the GLI equivalents, particularly for current
and former smokers.
Checking the Robustness of the
Temporal Trend of AO
On the basis of adjusted analysis including
education, VGDF, and COPD Roadshow,
we saw that the prevalence rates of having
GLI- or Hankinson-defined AO was 1.54
(95% CI, 1.22 to 1.93) and 1.65 (95% CI, 1.33
to 2.04) in the year 2012 compared with the
year 2003, respectively (Table 3). Therefore,
the upward trend of AO in the population
remained strong even after adjusting for
additional confounders. The full output for
the logistic regression model is provided in
Table E1 in the online supplement.
We repeated the loess smoothed plots
for adjusted GLI- and Hankinson-defined
AO and stratified by age group. For GLI-
defined AO, the prevalence rates were high
for those aged 65 years and older; however,
the prevalence for younger age groups
showed a steady increase over time (Figure
E2). The same was seen for Hankinson-
defined AO, which showed steady increases
for all age groups (Figure E3).
We restricted our sensitivity analysis to
participants in the Canton of Zurich
(n= 18,597). We ran adjusted Poisson
regression models and saw that the rate of
having GLI- or Hankinson-defined AO was
1.66 (95%CI, 1.19 to 2.29) and 1.74 (95%CI,
1.29 to 2.33) times higher in the year 2012
than in the year 2003, respectively (Table
E4). Therefore, even after accounting for the
LuftiBus traveling outside of Zurich more
often in the later years, the trend in AO from
2003 to 2012 still existed when limited to
one region.
We looked at participants who self-
reported as having asthma (n= 1,175) from
the 2004–2012 LuftiBus-SNC data to see
if they influenced prevalence. We plotted
GLI and Hankinson prevalence using the
adjusted Poisson models. Participants with
asthma had high rates of AO, but there was
no obvious time trend (Figures E5 and E6).
Last, we assessed self-reported
breathing difficulties and disease status
over time. We saw little change in those
who complained of breathing difficulties;
however, there were fluctuations across
disease status that included a decrease in
cough and bronchitis and cardiovascular
disease in those who did have AO (Table
E7). Ultimately, there were minimal changes
over the years in these items.
Discussion
In our series of 18 prevalence studies, we
found an increase in AO prevalence from
1993 to 2012. The rate of AO was 1.5 and 1.6
times higher in 2012 compared with 2003
when using the GLI and Hankinson
definitions, respectively, after extensive
adjustments to control for differences in
populations across the years.
Because the increases were substantial,
we dug deeper into the methodological
contributions by focusing on subpopulations
such as Zurich and self-reported asthma,
disease status, and breathing difficulties.
The increase still existed when we limited
the analysis to Zurich. Zurich is a good
representation of Switzerland and shows
little deviation from the general population,
which leads us to say there is an increase
in AO in the general population of
Switzerland.
The overall prevalence of AO in our
cohort in 2010 is 12.8% using GLI-defined
AO, which is close to the worldwide
estimated prevalence of COPD of 11.7% (2).
One of the strengths of the LuftiBus
campaign is the ability to adjust for many
confounders shown to influence AO. The
results of previous temporal trend studies
are inconsistent, limited to physician-
diagnosed COPD and adjustment for
confounding; are often limited to age, sex, or
smoking; and do not account for both air
pollution and occupational VGDF. We
observed an increase in prevalence,
regardless of smoking status or age group.
Although ambient air pollution levels
in Switzerland remained low during the
years of this cohort, a 2012 publication in
the Swiss Forestry Journal reported that air
pollution peaked from the 1960s to the
1990s (20, 29). The World Health
Organization reported on Swiss tobacco
trends (30), showing that per capita cigarette
consumption peaked in the 1970s and
1980s. Until 2010, there was little protection
of the population against passive smoking in
public spaces. We speculate that this
increase in air pollution, tobacco
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contribute to the increase trend in AO in our
study, given that the development of AO
takes decades.
In 2010, the Swiss federal government
passed a passive smoking law dictating
minimum requirements regarding smoking
in public spaces. Individual cantons could
impose stricter legislation. Since the
introduction of this law, smoking in
enclosed spaces open to the public or serving
as a workplace is prohibited (31). Because of
this improvement in air quality, it is possible
in the upcoming decades that we will see a
decrease in AO, assuming smoking and
environmental air pollutants play a role in
the prevalence trend. The increase in AO
may be a result of these environmental
factors before these restrictions.
Several studies have attempted to
explain the prevalence trends of AO in Italy,
Norway, and Spain (3, 4, 6), although none
of them is conclusive. Both the Italian and
Norwegian research groups found an
increase in AO prevalence, whereas the
Spanish research group reported a decrease.
The Italian research group suggested that
tobacco use, air pollutants, urban living
environment, and occupational exposures
seemed to be the primary sources of
increase in COPD. Our data showed that
occupational exposures to VGDF resulted in
3.1 and 3.2 times higher chance of AO when
using the GLI and Hankinson criteria of
diagnosis, respectively, after adjusting
for all other demographic variables. The
Norwegian study reported a similarly strong
increase in COPD prevalence from 1997 to
2005; however, it could be due to the
methodological design of their study. Their
dataset for 2007 comprised the second
follow-up data of a 20-year cohort study,
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Figure 2. Prevalence of airway obstruction (AO) as defined by the Global Lung Initiative annually from 1993 to 2012, stratified by sex and smoking status.
Dashed lines represent prevalence by smoking status; solid lines represent overall prevalence by sex; and solid lines at 2005 and 2011 along the x-axis
represent the time period when the spirometry device changed.
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could bias the temporal trend. For both the
Italian and Norwegian studies, using follow-
up data could have overestimated the
increase in prevalence because of an aging
study population. The Spanish research
group reported a decrease in prevalence of
COPD between the years 1997 and 2007,
different from many other studies on
temporal COPD trends. Their findings
could have potentially been affected by a
sicker population in 1997 than in 2007.
Our study has advantages, such as a
large sample size and the ability to match the
LuftiBus data with the Swiss census, to
model important risk factors. The
spirometry testing was performed with
trained staff who were required to undergo
training at least two times per year
conducted by an expert pulmonologist
according to strict guidelines. The
technicians tested the devices daily to ensure
precise calibration. However, the LuftiBus
was not based on a sampling procedure, and
those who participated did so voluntarily.
Given that public awareness of COPD,
asthma, and other pulmonary diseases has
increased over the years, those with
respiratory symptoms or chronic exposure
to VGDF may be more inclined to
participate. Participants may be less healthy
than the general population, resulting in a
volunteer bias, which could overestimate
both the absolute and adjusted prevalence
trends (32). The self-reported breathing
difficulties and disease status over time
showed no obvious time trend of a
sicker population. A 2015 World
Health Organization report on tobacco
consumption showed that Switzerland had a
20% prevalence of consumption in 2014,
similar to the 18% prevalence of smoking
we saw in our dataset (33). Our study
population was similarly comparable to the
general population regarding sex and age.
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Figure 3. Prevalence of airway obstruction (AO) defined by Hankinson annually from 1993 to 2012, stratified by sex and smoking status. Dashed lines
represent prevalence by smoking status; solid lines represent overall prevalence by sex; and solid lines at 2005 and 2011 along the x-axis represent the time
period when the spirometry device changed.
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argument that this sample is a population
sample and representative of the general
population in Switzerland, not necessarily
indicating a sicker population over the years.
The 1993–2002 data did not contain
sufficient information so that subjects could
be identified; thus, we were unable to
confirm if this dataset contained participants
included in the LuftiBus-SNC dataset from
2003 to 2012, for which we have patient-
identifiable information. This could lead to
participants’ being represented more than
once in the prevalence analysis. We have
repeat measurements (n= 3,269) from the
LuftiBus-SNC dataset from 2003 to 2012
that were unused in the analysis for this
study. We looked at the crude prevalence of
GLI- and Hankinson-defined AO and it
increases with each visit number. Regardless
of these considerations, any repeated
participants in the analysis from 1993 to 2012
would change neither the direction nor the
magnitude of the temporal prevalence trend,
because those participants are equally likely
to repeat in any year. Therefore, we would
still see an increase in AO.
Prebronchodilator measurements may
potentially overestimate the prevalence rates
compared with post-bronchodilator
measurements. A Norwegian study (4) had
both pre- and post-bronchodilator data and
found a 7% higher prevalence in the
prebronchodilator data than in the post-
bronchodilator data. This implies that we
could be overestimating the prevalence of
AO; however, this would not affect the
temporal trend we see.
Another limitation of the LuftiBus data
is that two-thirds of our study population
reside in Zurich. Therefore, although our
sample size is large, this could limit
generalizability. However, Zurich rarely
substantially deviates from the Swiss
average, and the age structure of the adult
population in the Canton of Zurich is very
similar to that of Switzerland as a whole.
Last, the multiple spirometer devices
used may bias the trend estimates because of
measurement error (34). The LuftiBus used
devices manufactured consistently from the
same company over the years (CareFusion is
the parent organization of SensorMedics).
Previous papers (35–37) have shown that
there is little difference between devices
when tested regularly, and devices used in a
pulmonary laboratory setting are more
accurate than those used in clinical practice.
A Norwegian paper that used both
SensorMedics Vmax devices found that the
Legacy was 2.5% lower, on average, for FEV1
values than the Encore, which, if adjusted for
in our study, would highlight a larger increase
in prevalence over time (38). Isolating the
Vmax Encore, in use from 2005 to 2010, the
trend increases from 9.4% to 12.2% for GLI-
defined AO, showing that even with one
device, we are still seeing an increase. Because
of these factors, it is reasonable to believe that
the trend over time from 1993 to 2012 is an
accurate indicator of an increase of AO and
not necessarily indicative of a sicker
population over the years.
There are substantial public health
implications of a true rise of AO prevalence.
The BOLD (Burden of Obstructive Lung
Disease) study (39) found that participants
with COPD were more likely to have heart
disease, hypertension, and diabetes. A
follow-up paper (40) suggested that severe
COPD could have a larger negative impact
on health status than cardiovascular disease
and diabetes. A rise in AO could increase
hospital use, medication use, and direct/
indirect medical costs if AO trends worsen
over time. An increase in AO in Switzerland
could also indicate an increase in other
countries with similar demographics, air
pollution trends, occupational exposures,
and rates of smoking. We speculate that this
increase in AO in Switzerland could be
indicative of what can be expected in other
countries if strong public health actions are
not taken against these risk factors.
AO seems to be increasing worldwide,
but only few studies have been done to
assess prevalence trends. Temporal
prevalence studies are essential in assessing
whether there is a true increase within
populations. Although it is well known that
smoking has a strong impact on the
incidence of AO, more needs to be done to
assess the environmental and occupational
impact on temporal AO trends.
Conclusions
We found that the prevalence of GLI-defined
AO increased from 6.1% to 15.6% over a 20-
year period. After adjusting for several well-
known risk factors for AO, we still observed a
statistically significant increase in the
prevalence over time when looking at a
decade of data. We feel confident in saying
that this is a true upward trend of AO in the
general Swiss population. n
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Table 3. Global Lung Initiative–, Hankinson-, and Global Initiative for Chronic Obstructive Lung Disease standard–defined airway
obstruction prevalence ratios compared with year 2003
Airway Obstruction
Definition
2004 2005 2006 2007 2008 2009 2010 2011 2012
GLI 0.65 0.81 0.90 1.22 0.98 1.19 0.98 1.36 1.54
95% CI 0.54–0.78 0.70–0.95 0.76–1.05 1.04–1.42 0.84–1.15 1.01–1.39 0.83–1.16 1.15–1.61 1.22–1.93
Hankinson 0.63 0.78 0.88 1.15 0.95 1.20 0.94 1.29 1.65
95% CI 0.53–0.76 0.68–0.90 0.76–1.03 0.99–1.34 0.82–1.11 1.03–1.39 0.80–1.10 1.10–1.52 1.33–2.04
GOLD 0.83 0.83 1.00 1.18 1.07 1.22 0.99 1.37 1.50
95% CI 0.74–0.93 0.76–0.91 0.91–1.09 1.08–1.30 0.98–1.18 1.11–1.33 0.89–1.09 1.24–1.50 1.33–1.70
Definition of abbreviations: CI = confidence interval; COPD=chronic obstructive pulmonary disease; GLI =Global Lung Initiative; GOLD=Global Initiative for
Chronic Obstructive Lung Disease.
The table shows prevalence ratios of havingGLI-, Hankinson-, or GOLD-defined airway obstruction comparedwith year 2003. The Poisson regressionswere
adjusted for age, sex, body mass index, smoking status, residential distance to major roads, education level, occupational exposure, urbanization,
participation in COPD Roadshow, altitude, and season of LuftiBus assessment. Note that at 2005 and 2011, the spirometry device changed.
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